Capricor Therapeutics Reports $33.9 Million Net Loss and Increased R&D Expenses for Q1 2026

Capricor Therapeutics, Inc. reported a net loss of approximately $33.9 million for the three months ended March 31, 2026, compared to a net loss of about $24.4 million for the same period in 2025. The company's total operating expenses increased to approximately $36.8 million, up from $25 million in the prior year, primarily driven by a significant rise in research and development costs, which reached $27.4 million, a 45% increase from $18.9 million in the previous year. The increase in R&D expenses was largely attributed to expanded manufacturing production and commercial-related expenses for its lead product candidate, Deramiocel, which is under review by the FDA for the treatment of Duchenne muscular dystrophy (DMD).

Capricor's financial position showed a decrease in cash and cash equivalents, which fell to approximately $105.4 million as of March 31, 2026, down from $287.8 million at the end of 2025. The company also reported marketable securities of $173.2 million, a significant increase from $30.3 million at the end of the previous year. The total assets of the company were approximately $326.3 million, while total liabilities stood at about $47.6 million, resulting in stockholders' equity of approximately $278.7 million.

In terms of strategic developments, Capricor has been actively pursuing commercialization agreements for Deramiocel. The company has entered into distribution agreements with Nippon Shinyaku for both the U.S. and Japan markets, with the latter agreement providing an upfront payment of $12 million and potential milestone payments of up to $89 million. However, Capricor is currently involved in litigation against Nippon Shinyaku, alleging breaches of the distribution agreement, which could impact its ability to market Deramiocel effectively.

Operationally, Capricor has expanded its workforce to support its R&D efforts, which has contributed to increased personnel costs. The company is also in discussions for a potential new facility in San Diego to enhance its manufacturing capabilities. As of March 31, 2026, Capricor had no revenue from product sales, reflecting its status as a clinical-stage biotechnology company focused on developing innovative therapies for DMD and other diseases.

Looking ahead, Capricor anticipates continued significant operating losses as it invests in the development and potential commercialization of Deramiocel and its exosome platform technologies. The company expects to incur substantial expenses related to clinical trials and regulatory approvals, and it may seek additional funding through equity or debt financing to support its operations. The outcome of its litigation with Nippon Shinyaku and the FDA's review of Deramiocel will be critical in determining the company's future financial performance and operational strategy.